Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis

Leverages proprietary pan-amyloid targeting agents with potential to diagnose and reverse the underlying pathology of systemic amyloid diseases, including AL and ATTR amyloidosis

SOUTH SAN FRANCISCO, Calif., September 14, 2020 – Attralus, a biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis, today announced the completion of its $25 million Series A financing. The Series A financing was led by venBio Partners and will allow Attralus to further validate their pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain) and potentially ALECT2 systemic amyloidosis.  

Attralus expects to file IND applications for the two therapeutics programs by early 2022. Systemic amyloidosis encompasses a diverse group of approximately 30 different disorders that occur due to protein misfolding, which produces amyloid fibrils that accumulate in multiple organs throughout the body. Deposited amyloid is toxic to organs and tissues and causes significant dysfunction. All forms of systemic amyloidosis, including AL, ATTR and ALECT2, can affect multiple major organs and tissues, including the heart, kidneys, liver, gastrointestinal tract and nerves. Patients with amyloidosis experience a broad range of severely debilitating symptoms such as heart failure, kidney failure and neuropathy, and most patients have less than five years of life expectancy from onset of symptoms.